Odevixibat

Last updated

Odevixibat
Odevixibat structure.png
Clinical data
Trade names Bylvay
Other namesA4250
License data
Routes of
administration 		By mouth
ATC code
Legal status
Legal status
Identifiers
  • (2S)-2-{[(2R)-2-[({[3,3-Dibutyl-7-(methylsulfanyl)-1,1-dioxido-5-phenyl-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepin-8-yl]oxy}acetyl)amino]-2-(4-hydroxyphenyl)acetyl]amino}butanoic acid
CAS Number
PubChem CID
IUPHAR/BPS
DrugBank
ChemSpider
UNII
KEGG
ChEMBL
Chemical and physical data
Formula C37H48N4O8S2
Molar mass 740.93 g·mol−1
3D model (JSmol)
  • CCCCC1(CCCC)CN(C2=CC=CC=C2)C2=CC(SC)=C(OCC(=O)N[C@@H](C(=O)N[C@@H](CC)C(O)=O)C3=CC=C(O)C=C3)C=C2S(=O)(=O)N1
  • InChI=1S/C37H48N4O8S2/c1-5-8-19-37(20-9-6-2)24-41(26-13-11-10-12-14-26)29-21-31(50-4)30(22-32(29)51(47,48)40-37)49-23-33(43)39-34(25-15-17-27(42)18-16-25)35(44)38-28(7-3)36(45)46/h10-18,21-22,28,34,40,42H,5-9,19-20,23-24H2,1-4H3,(H,38,44)(H,39,43)(H,45,46)/t28-,34+/m0/s1
  • Key:XULSCZPZVQIMFM-IPZQJPLYSA-N

Odevixibat, sold under the brand name Bylvay, is a medication for the treatment of progressive familial intrahepatic cholestasis. [1] [4] It is taken by mouth. [1] Odevixibat is a reversible, potent, selective inhibitor of the ileal bile acid transporter (IBAT). [4] [5] [6] It was developed by Albireo Pharma. [7]

Contents

The most common side effects include diarrhea, abdominal pain, hemorrhagic diarrhea, soft feces, and hepatomegaly (enlarged liver). [4]

Odevixibat was approved for medical use in the United States and in the European Union in July 2021. [1] [2] [3] [8] [9] The U.S. Food and Drug Administration considers it to be a first-in-class medication. [10]

Medical uses

In the United States, odevixibat is indicated for the treatment of pruritus in people three months of age and older with progressive familial intrahepatic cholestasis. [1] In the European Union it is indicated in people six months of age and older. [2] [3]

Mechanism of action

Odevixibat is a reversible inhibitor of the ileal sodium/bile acid co-transporter. This transporter is responsible for reabsorption of the majority of bile acids in the distal ileum. [11] The reduced absorption of the bile acids in the distal ileum compounds and leads to a decrease in stimulation of FXR (farnesoid X receptor), decreasing the inhibition of bile acid synthesis. [12]

Odevixibat works as a reversible, selective, small molecule inhibitor of the ileal bile acid transporter (IBAT). [4] [6]

Pharmacokinetics

Odevixibat is > 99% protein-bound in vitro. [12] A dose of odevixibat that is 7.2 mg reaches a cmax concentration of 0.47 ng/mL with an AUC (0-24h) of 2.19 h*ng/mL. [12] Adult and pediatric patients given the therapeautic dose of odevixibat did not display plasma concentrations of the drug. [9] Odevixibat is eliminated majorly unchanged. [12] Odevixibat has an average half-life of 2.36 hours. [12]

The peak plasma time ranges from 1 to 5 hours after a single 7.2 mg dose in healthy adults. In healthy adults receiving a single 7.2 mg dose, the peak plasma concentration is 0.47 ng/mL, and the area under the concentration-time curve (AUC) is 2.19 ng·hr/mL. The plasma concentration of odevixibat in patients aged 6 months to 17 years ranges from 0.06 to 0.72 ng/mL. With once-daily dosing, there is no accumulation of odevixibat. [13]

Odevixibat is metabolized through a process called mono-hydroxylation.The drug is primarily eliminated through the feces (97% unchanged), with a minimal amount excreted in the urine (0.002%). [14]

Consuming a high-fat meal (800-1000 calories with approximately 50% of the total caloric content from fat) the peak plasma concentration is decreased by 72%, the AUC by 62%, and delays the peak plasma time by 3 to 4.5 hours. However, the impact of food on systemic exposures to odevixibat is not clinically significant. [15]

Contraindications

Odevixibat cannot be given to a child on a liquid diet. [12]

Adverse effects

Common side effects of odevixibat include diarrhea, stomach pain, vomiting, liver test abnormalities, abnormal liquid function tests, and a deficiency in vitamins A, D, E and K. [16] [12]

Pregnancy and lactation

There are no enough human data on odevixibat use during pregnancy to build a drug-associated risk of major birth defects, miscarriage, or adverse developmental outcomes. [16]

There are no data on the presence of odevixibat in human milk, and how it affects milk production and breastfed babies. [16]

History

Preclinical studies and early clinical trials were conducted to evaluate the safety and efficacy of odevixibat, to establish the appropriate dosage, assess its mechanism of action, and evaluate its effects on bile acid levels and symptoms in people with progressive familial intrahepatic cholestasis. A 24-week clinical trial, played a role in demonstrating the effectiveness and safety of odevixibat in treating pruritus in children with progressive familial intrahepatic cholestasis. [14]

The US Food and Drug Administration (FDA) granted the application for odevixibat orphan drug designation. [10] The FDA classified odevixibat as an orphan drug for the rare conditions of Alagille syndrome, biliary atresia, and primary biliary cholangitis. [16]

Odevixibat was granted its initial approval in July 2021, in the European Union for the treatment of progressive familial intrahepatic cholestasis in people aged six months and older. In July 2021, it received approval in the United States for the treatment of pruritus (itching) in people aged three months and older with progressive familial intrahepatic cholestasis. [17]

Society and culture

In May 2021, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) recommended granting a marketing authorization in the European Union for odevixibat for the treatment of progressive familial intrahepatic cholestasis in people aged six months or older. [4] [18] It was approved for medical use in the European Union in July 2021. [2] [3]

Research

A phase III randomized control trial showed odevixibat reduced pruritis and serum bile acids in children with progressive familial intrahepatic cholestasis. [19]

Related Research Articles

<span class="mw-page-title-main">Ursodeoxycholic acid</span> Metabolite of cholesterol

Ursodeoxycholic acid (UDCA), also known as ursodiol, is a secondary bile acid, produced in humans and most other species from metabolism by intestinal bacteria. It is synthesized in the liver in some species, and was first identified in bile of bears of genus Ursus, from which its name derived. In purified form, it has been used to treat or prevent several diseases of the liver or bile ducts.

<span class="mw-page-title-main">Colestyramine</span> Pharmaceutical drug

Colestyramine (INN) or cholestyramine (USAN) is a bile acid sequestrant, which binds bile in the gastrointestinal tract to prevent its reabsorption. It is a strong ion exchange resin, which means it can exchange its chloride anions with anionic bile acids in the gastrointestinal tract and bind them strongly in the resin matrix. The functional group of the anion exchange resin is a quaternary ammonium group attached to an inert styrene-divinylbenzene copolymer.

<span class="mw-page-title-main">Cholestasis</span> Medical condition

Cholestasis is a condition where the flow of bile from the liver to the duodenum is impaired. The two basic distinctions are:

<span class="mw-page-title-main">Irinotecan</span> Cancer medication

Irinotecan, sold under the brand name Camptosar among others, is a medication used to treat colon cancer, and small cell lung cancer. For colon cancer it is used either alone or with fluorouracil. For small cell lung cancer it is used with cisplatin. It is given intravenously.

Progressive familial intrahepatic cholestasis (PFIC) is a group of familial cholestatic conditions caused by defects in biliary epithelial transporters. The clinical presentation usually occurs first in childhood with progressive cholestasis. This usually leads to failure to thrive, cirrhosis, and the need for liver transplantation.

Ipsen is a French biopharmaceutical company headquartered in Paris, France, with a focus on transformative medicines in three therapeutic areas: oncology, rare disease and neuroscience. Ipsen is one of the world's top 15 biopharmaceutical companies in terms of oncology sales.

<span class="mw-page-title-main">Intrahepatic cholestasis of pregnancy</span> Medical condition

Intrahepatic cholestasis of pregnancy (ICP), also known as obstetric cholestasis, cholestasis of pregnancy, jaundice of pregnancy, and prurigo gravidarum, is a medical condition in which cholestasis occurs during pregnancy. It typically presents with itching and can lead to complications for both mother and fetus.

<span class="mw-page-title-main">ABCB11</span> Protein-coding gene in the species Homo sapiens

ATP-binding cassette, sub-family B member 11 (ABCB11), also known as the bile salt export pump (BSEP), is a protein which in humans is encoded by the ABCB11 gene.

<span class="mw-page-title-main">Ileal sodium/bile acid cotransporter</span> Protein-coding gene in the species Homo sapiens

Ileal sodium/bile acid cotransporter, also known as apical sodium–bile acid transporter (ASBT) and ileal bile acid transporter (IBAT), is a bile acid:sodium symporter protein that in humans is encoded by the SLC10A2 gene.

<span class="mw-page-title-main">Rilpivirine</span> HIV treatment

Rilpivirine, sold under the brand names Edurant and Rekambys, is a medication, developed by Tibotec, used for the treatment of HIV/AIDS. It is a second-generation non-nucleoside reverse transcriptase inhibitor (NNRTI) with higher potency, longer half-life and reduced side-effect profile compared with older NNRTIs such as efavirenz.

<span class="mw-page-title-main">Tafamidis</span> Medication for transthyretin amyloidosis

Tafamidis, sold under the brand names Vyndaqel and Vyndamax, is a medication used to delay disease progression in adults with certain forms of transthyretin amyloidosis. It can be used to treat both hereditary forms, familial amyloid cardiomyopathy and familial amyloid polyneuropathy, as well as wild-type transthyretin amyloidosis, which formerly was called senile systemic amyloidosis. It works by stabilizing the quaternary structure of the protein transthyretin. In people with transthyretin amyloidosis, transthyretin falls apart and forms clumps called (amyloid) that harm tissues including nerves and the heart.

<span class="mw-page-title-main">Nintedanib</span> Chemical compound

Nintedanib, sold under the brand names Ofev and Vargatef, is an oral medication used for the treatment of idiopathic pulmonary fibrosis and along with other medications for some types of non-small-cell lung cancer.

<span class="mw-page-title-main">Elobixibat</span> Chemical compound

Elobixibat is an inhibitor of the ileal bile acid transporter (IBAT), undergoing development in clinical trials for the treatment of chronic constipation and irritable bowel syndrome with constipation (IBS-C).

<span class="mw-page-title-main">Cabotegravir</span> Preventative exposure drug for the prevention of HIV/AIDS

Cabotegravir, sold under the brand name Vocabria among others, is a antiretroviral medication used for the treatment of HIV/AIDS. It is available in the form of tablets and as an intramuscular injection, as well as in an injectable combination with rilpivirine under the brand name Cabenuva.

<span class="mw-page-title-main">Obeticholic acid</span> Chemical compound

Obeticholic acid (OCA), sold under the brand name Ocaliva, is a semi-synthetic bile acid analogue which has the chemical structure 6α-ethyl-chenodeoxycholic acid. It is used as a medication used to treat primary biliary cholangitis. Intercept Pharmaceuticals Inc. hold the worldwide rights to develop OCA outside Japan and China, where it is licensed to Dainippon Sumitomo Pharma.

<span class="mw-page-title-main">Lorlatinib</span> Kinase inhibitor for treatment of non-small-cell lung cancer

Lorlatinib, sold under the brand name Lorbrena in the United States, Canada, and Japan, and Lorviqua in the European Union, is an anti-cancer drug developed by Pfizer. It is an orally administered inhibitor of ALK and ROS1, two enzymes that play a role in the development of cancer.

Bempedoic acid, sold under the brand name Nexletol among others, is a medication for the treatment of hypercholesterolemia.

<span class="mw-page-title-main">Cenobamate</span> Chemical compound

Cenobamate, sold under the brand names Xcopri (US) and Ontozry (EU), is a medication used for the treatment of partial-onset seizures, a kind of epilepsy, in adults. It is taken by mouth.

Bempedoic acid/ezetimibe, sold under the brand name Nexlizet among others, is a fixed-dose combination medication used for the treatment of high cholesterol. It is a combination of bempedoic acid and ezetimibe.

<span class="mw-page-title-main">Maralixibat chloride</span> Chemical compound

Maralixibat chloride, sold under the brand name Livmarli, is a medication used to treat cholestatic pruritus in people with Alagille syndrome. Maralixibat chloride is an ileal bile acid transporter (IBAT) inhibitor.

References

  1. 1 2 3 4 5 "Bylvay- odevixibat capsule, coated pellets". DailyMed. U.S. National Library of Medicine. Archived from the original on 29 July 2021. Retrieved 28 July 2021.
  2. 1 2 3 4 "Bylvay EPAR". European Medicines Agency (EMA). 20 April 2021. Archived from the original on 29 July 2021. Retrieved 28 July 2021.
  3. 1 2 3 4 "Bylvay". Union Register of medicinal products. Archived from the original on 24 July 2021. Retrieved 23 July 2021.
  4. 1 2 3 4 5 "First treatment for rare liver disease". European Medicines Agency (EMA) (Press release). 21 May 2021. Retrieved 21 May 2021. Text was copied from this source which is © European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
  5. ↑ "Odevixibat". Albireo Pharma. Archived from the original on 22 May 2021. Retrieved 21 May 2021.
  6. 1 2 Karpen SJ, Kelly D, Mack C, Stein P (September 2020). "Ileal bile acid transporter inhibition as an anticholestatic therapeutic target in biliary atresia and other cholestatic disorders". Hepatology International. 14 (5): 677–689. doi:10.1007/s12072-020-10070-w. PMID   32653991. S2CID   220481607.
  7. ↑ Deeks ED (October 2021). "Odevixibat: First Approval". Drugs. 81 (15): 1781–1786. doi:10.1007/s40265-021-01594-y. PMC   8550539 . PMID   34499340.
  8. ↑ "Odevixibat: FDA-Approved Drugs". U.S. Food and Drug Administration (FDA). Archived from the original on 27 September 2021. Retrieved 23 July 2021.
  9. 1 2 "Albireo Announces FDA Approval of Bylvay (odevixibat), the First Drug Treatment for Patients With Progressive Familial Intrahepatic Cholestasis (PFIC)". Albireo Pharma (Press release). 20 July 2021. Retrieved 23 July 2021– via GlobeNewswire.
  10. 1 2 Advancing Health Through Innovation: New Drug Therapy Approvals 2021 (PDF). U.S. Food and Drug Administration (FDA) (Report). 13 May 2022. Archived from the original on 6 December 2022. Retrieved 22 January 2023.PD-icon.svg This article incorporates text from this source, which is in the public domain .
  11. ↑ "Odevixibat". go.drugbank.com. Archived from the original on 19 September 2021. Retrieved 13 June 2022.
  12. 1 2 3 4 5 6 7 "Odevixibat Monograph for Professionals". Drugs.com. 30 August 2022. Archived from the original on 15 December 2022. Retrieved 6 July 2023.
  13. ↑ Yu S, Wang D, Yu J, Yin Y, Xie S, Cheng Q, et al. (May 2021). "Plasma or serum, which is the better choice for the measurement of metanephrines?". Scandinavian Journal of Clinical and Laboratory Investigation. 81 (3): 250–253. doi:10.1080/00365513.2021.1904280. PMID   33787416. S2CID   232430232. Archived from the original on 7 July 2023. Retrieved 7 July 2023.
  14. 1 2 Ray K (September 2022). "Positive phase III results for odevixibat for progressive familial intrahepatic cholestasis". Nature Reviews. Gastroenterology & Hepatology. 19 (9): 556. doi:10.1038/s41575-022-00667-x. PMID   35879356. S2CID   251021808.
  15. ↑ Taylor L, Gidal B, Blakey G, Tayo B, Morrison G (November 2018). "A Phase I, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose, Multiple Dose, and Food Effect Trial of the Safety, Tolerability and Pharmacokinetics of Highly Purified Cannabidiol in Healthy Subjects". CNS Drugs. 32 (11): 1053–1067. doi:10.1007/s40263-018-0578-5. PMC   6223703 . PMID   30374683. Archived from the original on 7 July 2023. Retrieved 7 July 2023.
  16. 1 2 3 4 Porwal M, Kumar A, Rastogi V, Maheshwari KK, Verma A (March 2023). "Odevixibat: A Review of a Bioactive Compound for the Treatment of Pruritus Approved by the FDA". Current Drug Research Reviews. 15: 32–42. doi:10.2174/2589977515666230308125238. PMID   36892028. S2CID   257426837.
  17. ↑ Deeks ED (October 2021). "Odevixibat: First Approval". Drugs. 81 (15): 1781–1786. doi:10.1007/s40265-021-01594-y. PMC   8550539 . PMID   34499340. Archived from the original on 7 July 2023. Retrieved 7 July 2023.
  18. ↑ "Bylvay: Pending EC decision". European Medicines Agency (EMA). 19 May 2021. Archived from the original on 21 May 2021. Retrieved 21 May 2021.
  19. ↑ Thompson RJ, Arnell H, Artan R, Baumann U, Calvo PL, Czubkowski P, et al. (September 2022). "Odevixibat treatment in progressive familial intrahepatic cholestasis: a randomised, placebo-controlled, phase 3 trial". The Lancet. Gastroenterology & Hepatology. 7 (9): 830–842. doi:10.1016/S2468-1253(22)00093-0. PMID   35780807. S2CID   250229742.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.